Letter

Selective serotonin reuptake inhibitors

BMJ 2005; 330 doi: 10.1136/bmj.330.7488.420-b (Published 17 February 2005)
Cite this as: BMJ 2005;330:420.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

THREAD trial may show way forward

  1. Robert Peveler, professor of liaison psychiatry (rcp@soton.ac.uk),
  2. Tony Kendrick, professor of primary medical care,
  3. THREAD Study Group
  1. University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG
  2. University of Southampton, Aldermoor Health Centre, Southampton SO16 5ST

    EDITOR—Geddes and Cipriani comment that available randomised evidence does not provide reliable estimates of the costs and benefits of treatment with selective serotonin reuptake inhibitors (SSRIs) in patients with varying degrees of severity and laments the decline in non-commercial funding.1 Recent guidelines from the National Institute for National Excellence (NICE) also lack evidence.2 The NHS health technology assessment programme is funding a trial …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular